首页> 外文期刊>Behavioural Brain Research: An International Journal >The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats
【24h】

The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats

机译:双重作用的H3受体拮抗剂和AChE抑制剂UW-MD-71剂量依赖性地增强记忆力恢复并逆转地佐西平诱发的大鼠记忆力障碍

获取原文
获取原文并翻译 | 示例
           

摘要

Both the histamine H3 receptor (H3R) and acetylcholine esterase (AChE) are involved in the regulation of release and metabolism of acetylcholine and several other central neurotransmitters. Therefore, dual-active H3R antagonists and AChE inhibitors (AChEIs) have shown in several studies to hold promise to treat cognitive disorders like Alzheimer's disease (AD). The novel dual-acting H3R antagonist and AChEI 7-(3-(piperidin-1-yl)propoxy)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline (UW-MD-71) with excellent selectivity profiles over both the three other HRs as well as the AChE's isoenzyme butyrylcholinesterase (BChE) shows high and balanced in vitro affinities at both H3R and AChE with IC50 of 33.9 nM and hH3R antagonism with K-i of 76.2 nM, respectively. In the present study, the effects of UW-MD-71 (1.25-5 mg/kg, i.p.) on acquisition, consolidation, and retrieval in a one-trial inhibitory avoidance task in male rats were investigated applying donepezil (DOZ) and pitolisant (PIT) as reference drugs. Furthermore, the effects of UV-MD-71 on memory deficits induced by the non-competitive N-methyl-D-aspartate (NMDA) antagonist dizocilpine (DIZ) were tested. Our results indicate that administration of UW-MD-71 before the test session dose-dependently increased performance and enhanced procognitive effect on retrieval. However neither pre- nor post-training acute systemic administration of UW-MD-71 facilitated acquisition or consolidation. More importantly, UW-MD-71 (2.5 mg/kg, i.p.) ameliorated the DIZ-induced amnesic effects. Furthermore, the procognitive activity of UW-MD-71 in retrieval was completely reversed and partly abrogated in DIZ-induced amnesia when rats were pretreated with the centrally-acting H2R antagonist zolantidine (ZOL), but not with the CNS penetrant H1R antagonist pyrilamine (PYR). These results demonstrate the procognitive effects of UW-MD-71 in two in vivo memory models, and are to our knowledge the first demonstration in vivo that a potent dual-acting H3R antagonist and AChEI is effective in improving retrieval processes in the one-trial inhibitory avoidance task and provide evidence to such compounds to treat cognitive disorders. (C) 2015 Elsevier B.V. All rights reserved.
机译:组胺H3受体(H3R)和乙酰胆碱酯酶(AChE)均参与乙酰胆碱和其他一些中枢神经递质的释放和代谢调节。因此,双重活性的H3R拮抗剂和AChE抑制剂(AChEIs)在多项研究中显示出有望治疗认知障碍,例如阿尔茨海默氏病(AD)。新型双作用H3R拮抗剂和AChEI 7-(3-(3-哌啶-1-基)丙氧基)-1,2,3,9-四氢吡咯并[2,1-b]喹唑啉(UW-MD-71)在其他三个HR以及AChE的同工酶丁酰胆碱酯酶(BChE)上的选择性谱显示,H3R和AChE的体外亲和力均很高且平衡,IC50为33.9 nM,hH3R拮抗作用的Ki50分别为76.2 nM。在本研究中,使用多奈哌齐(DOZ)和pitolisant研究了UW-MD-71(1.25-5 mg / kg,ip)对雄性大鼠的一次试验性避免回避行为中的获取,巩固和恢复的影响(PIT)作为参考药物。此外,测试了UV-MD-71对非竞争性N-甲基-D-天门冬氨酸(NMDA)拮抗剂二唑西平(DIZ)诱导的记忆缺陷的影响。我们的结果表明,在测试前给予UW-MD-71剂量依赖性地提高了性能并增强了对检索的认知作用。但是,训练前和训练后的UW-MD-71急性全身给药均不能促进采集或巩固。更重要的是,UW-MD-71(2.5 mg / kg,i.p.)改善了DIZ引起的记忆删除效果。此外,用中枢作用的H2R拮抗剂佐兰定(ZOL)预处理大鼠,但不使用CNS渗透性H1R拮抗剂吡咯胺(U)预处理时,UW-MD-71在恢复中的认知活性被完全逆转并且在DIZ诱发的失忆症中被部分废除。 PYR)。这些结果证明了UW-MD-71在两种体内记忆模型中的认知作用,并且据我们所知,这是体内首次证实有效的双重作用H3R拮抗剂和AChEI可有效改善一次试验中的检索过程。抑制性回避任务,并为此类化合物治疗认知障碍提供证据。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号